What If You Could Have An Injection Every Two Months to Prevent HIV? Apretude in Canada

Send us a text

Discover how a groundbreaking medical advancement is set to transform HIV prevention! Listen as Jean-Francois Fortin, Medical Director of Viive Canada, breaks down the approval process for Apertude—an extended-release injectable suspension for pre-exposure prophylaxis (PrEP), recently green lit by Health Canada. Compare its unique dosing regimen with traditional daily oral PrEP options and learn how Apertude's innovative approach promises to significantly enhance medication compliance and reduce HIV transmission rates in Canada.

We also delve into the pivotal clinical trials HPTN 083 and HPTN 084 that established the efficacy and safety of Apertude across diverse populations. Michael Kwagg from the Community-Based Research Center (CBRC) joins the conversation to highlight the profound impact this approval could have on various communities affected by HIV. Together, we explore the essential role of community organizations and healthcare providers in ensuring these advancements reach marginalized groups, encouraging more widespread testing and engagement in prevention strategies. Don't miss this crucial discussion on the future of HIV prevention.

Support the show